Rosetta Genomics (ROSG +15.6%) continues its volatile trajectory, jumping higher today after...

|About: Rosetta Genomics Ltd. (ROSG)|By:, SA News Editor

Rosetta Genomics (ROSG +15.6%) continues its volatile trajectory, jumping higher today after announcing that data from studies of miRview mets2 in patients with cancer were published online in The Oncologist. The study demonstrated the ability of the miRview mets2 assay to identify 42 tumor types with high accuracy.